Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
NCT ID NCT05283330
First seen Jan 25, 2026 · Last updated Jun 21, 2026 · Updated 17 times
Summary
This early-stage trial tests a new drug called 212Pb-DOTAM-GRPR1, which delivers a tiny dose of radiation directly to cancer cells that have a specific marker (GRPR). The study will include 48 adults with advanced cancers such as prostate, breast, lung, colon, cervical, or brain cancer that have come back or spread. The main goal is to find a safe dose and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Molecular Imaging and Therapy
RECRUITINGGlen Burnie, Maryland, 21061, United States
Contact Phone: •••-•••-••••
Contact
-
Nebraska Cancer Specialists (Midwest Cancer Center - Legacy)
RECRUITINGOmaha, Nebraska, 68130, United States
Contact
-
Northwestern University Robert H Lurie Medical Research
ACTIVE_NOT_RECRUITINGChicago, Illinois, 60611, United States
-
UK Markey Cancer Center
RECRUITINGLexington, Kentucky, 40536, United States
Contact Phone: •••-•••-••••
Contact
-
United Theranostics - Chesapeake
NOT_YET_RECRUITINGGlen Burnie, Maryland, 21061, United States
Contact
-
University of Iowa Health Care
NOT_YET_RECRUITINGIowa City, Iowa, 52242, United States
Contact
-
University of Pittsburg Medical Center (UPCM)
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15219, United States
Contact
-
XCancer Omaha / Urology Cancer Center
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
212Pb-DOTAM-GRPR1 (a radioactive drug that targets GRPR on cancer cells)
What this could lead to
If it works, this could offer a new treatment option for several advanced cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 48 participants, so safety and effectiveness are not yet known. The drug may cause side effects from radiation or may not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.